Fintel reports that on March 24, 2025, JP Morgan upgraded their outlook for Alnylam Pharmaceuticals (NasdaqGS:ALNY) from Neutral to Overweight.
Analyst Price Forecast Suggests 11.73% Upside
As of March 20, 2025, the average one-year price target for Alnylam Pharmaceuticals is $316.59/share. The forecasts range from a low of $196.95 to a high of $525.00. The average price target represents an increase of 11.73% from its latest reported closing price of $283.34 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Alnylam Pharmaceuticals is 2,991MM, an increase of 33.04%. The projected annual non-GAAP EPS is -2.24.
What is the Fund Sentiment?
There are 1,243 funds or institutions reporting positions in Alnylam Pharmaceuticals. This is an increase of 51 owner(s) or 4.28% in the last quarter. Average portfolio weight of all funds dedicated to ALNY is 0.41%, an increase of 10.52%. Total shares owned by institutions increased in the last three months by 5.03% to 163,599K shares. 
The put/call ratio of ALNY is 0.74, indicating a bullish outlook.
What are Other Shareholders Doing?
Capital World Investors holds 16,601K shares representing 12.82% ownership of the company. In its prior filing, the firm reported owning 16,508K shares , representing an increase of 0.55%. The firm decreased its portfolio allocation in ALNY by 15.75% over the last quarter.
AGTHX - GROWTH FUND OF AMERICA holds 10,568K shares representing 8.16% ownership of the company. In its prior filing, the firm reported owning 10,609K shares , representing a decrease of 0.39%. The firm decreased its portfolio allocation in ALNY by 10.78% over the last quarter.
Capital Research Global Investors holds 6,969K shares representing 5.38% ownership of the company. In its prior filing, the firm reported owning 5,244K shares , representing an increase of 24.75%. The firm increased its portfolio allocation in ALNY by 12.47% over the last quarter.
Regeneron Pharmaceuticals holds 4,444K shares representing 3.43% ownership of the company.
T. Rowe Price Investment Management holds 4,384K shares representing 3.39% ownership of the company. In its prior filing, the firm reported owning 3,139K shares , representing an increase of 28.40%. The firm increased its portfolio allocation in ALNY by 22.24% over the last quarter.
Alnylam Pharmaceuticals Background Information
(This description is provided by the company.)
Alnylam Pharmaceuticals Inc. is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam's commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), and OXLUMO™ (lumasiran) and Leqvio® (inclisiran) being developed and commercialized by Alnylam's partner Novartis. Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its 'Alnylam P5x25' strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
